Loading...

ResApp Health

DB:NUG
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NUG
DB
A$101M
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

ResApp Health Limited develops and commercializes the ResApp technology to provide health care solutions for respiratory diseases. The last earnings update was 80 days ago. More info.


Add to Portfolio Compare Print
  • ResApp Health has significant price volatility in the past 3 months.
NUG Share Price and Events
7 Day Returns
-14.9%
DB:NUG
5%
DE Healthcare Services
-0.2%
DE Market
1 Year Returns
0%
DB:NUG
33.5%
DE Healthcare Services
-10.3%
DE Market
NUG Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ResApp Health (NUG) -14.9% 14.3% 66.7% 0% - -
DE Healthcare Services 5% 13.3% 20% 33.5% 60.1% 211.2%
DE Market -0.2% -2.4% 4.2% -10.3% 11.2% 10.8%
1 Year Return vs Industry and Market
  • NUG underperformed the Healthcare Services industry which returned 33.5% over the past year.
  • NUG outperformed the Market in Germany which returned -10.3% over the past year.
Price Volatility
NUG
Industry
5yr Volatility vs Market

Value

 Is ResApp Health undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for ResApp Health. This is due to cash flow or dividend data being unavailable. The share price is €0.08.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ResApp Health's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ResApp Health's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:NUG PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$-0.01
ASX:RAP Share Price ** ASX (2019-05-17) in AUD A$0.15
Germany Healthcare Services Industry PE Ratio Median Figure of 6 Publicly-Listed Healthcare Services Companies 26.07x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.17x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ResApp Health.

DB:NUG PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:RAP Share Price ÷ EPS (both in AUD)

= 0.15 ÷ -0.01

-14.48x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ResApp Health is loss making, we can't compare its value to the DE Healthcare Services industry average.
  • ResApp Health is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does ResApp Health's expected growth come at a high price?
Raw Data
DB:NUG PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -14.48x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
96.3%per year
Europe Healthcare Services Industry PEG Ratio Median Figure of 12 Publicly-Listed Healthcare Services Companies 2.34x
Germany Market PEG Ratio Median Figure of 273 Publicly-Listed Companies 1.53x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ResApp Health, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ResApp Health's assets?
Raw Data
DB:NUG PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.01
ASX:RAP Share Price * ASX (2019-05-17) in AUD A$0.15
Germany Healthcare Services Industry PB Ratio Median Figure of 7 Publicly-Listed Healthcare Services Companies 2.32x
Germany Market PB Ratio Median Figure of 576 Publicly-Listed Companies 1.77x
DB:NUG PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:RAP Share Price ÷ Book Value per Share (both in AUD)

= 0.15 ÷ 0.01

10.8x

* Primary Listing of ResApp Health.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ResApp Health is overvalued based on assets compared to the DE Healthcare Services industry average.
X
Value checks
We assess ResApp Health's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. ResApp Health has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is ResApp Health expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
96.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ResApp Health expected to grow at an attractive rate?
  • ResApp Health's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • ResApp Health's earnings growth is expected to exceed the Germany market average.
  • ResApp Health's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:NUG Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:NUG Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 96.3%
DB:NUG Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 138.6%
Germany Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 2.5%
Europe Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 7%
Germany Market Earnings Growth Rate Market Cap Weighted Average 13.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:NUG Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:NUG Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-06-30 22 12 14 1
2020-06-30 2 -5 -5 1
2019-06-30 0 -5 -7 1
DB:NUG Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 0 -6 -7
2018-09-30 0 -6 -7
2018-06-30 -5 -7
2018-03-31 -6 -6
2017-12-31 0 -6 -6
2017-09-30 0 -6 -8
2017-06-30 -5 -10
2017-03-31 -4 -10
2016-12-31 -3 -9
2016-09-30 -3 -6
2016-06-30 -2 -3
2016-03-31 0 -2 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • ResApp Health's earnings are expected to grow significantly at over 20% yearly.
  • ResApp Health's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:NUG Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from ResApp Health Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NUG Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-06-30 0.02 0.02 0.02 1.00
2020-06-30 -0.01 -0.01 -0.01 1.00
2019-06-30 -0.01 -0.01 -0.01 1.00
DB:NUG Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 -0.01
2018-09-30 -0.01
2018-06-30 -0.01
2018-03-31 -0.01
2017-12-31 -0.01
2017-09-30 -0.01
2017-06-30 -0.02
2017-03-31 -0.02
2016-12-31 -0.02
2016-09-30 -0.01
2016-06-30 -0.01
2016-03-31 0.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • ResApp Health is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess ResApp Health's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ResApp Health has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has ResApp Health performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ResApp Health's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ResApp Health does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare ResApp Health's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare ResApp Health's 1-year growth to the DE Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
ResApp Health's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ResApp Health Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NUG Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.05 -6.68 3.61 3.99
2018-09-30 0.02 -6.61 3.68 3.86
2018-06-30 -6.53 3.75 3.73
2018-03-31 -6.10 3.56 3.82
2017-12-31 0.00 -5.67 3.37 3.90
2017-09-30 0.00 -7.85 5.50 3.68
2017-06-30 -10.03 7.64 3.46
2017-03-31 -9.65 7.49 2.65
2016-12-31 -9.26 7.33 1.84
2016-09-30 -6.23 4.76 1.47
2016-06-30 -3.21 2.19 1.09
2016-03-31 0.00 -2.61 1.85 0.82
2015-12-31 0.01 -2.01 1.51 0.55
2015-09-30 0.01 -1.25 1.08 0.28
2015-06-30 0.01 -0.49 0.66
2015-03-31 0.00 -0.42 0.58
2014-12-31 -0.35 0.50
2014-09-30 -0.46 0.54
2014-06-30 -0.58 0.58
2014-03-31 0.00 -0.56 0.62
2013-12-31 0.00 -0.55 0.67
2013-09-30 0.00 -0.73 0.80
2013-06-30 0.00 -0.92 0.94
2013-03-31 0.00 -1.03 1.00
2012-12-31 0.00 -1.15 1.07
2012-09-30 0.00 -0.99 0.98
2012-06-30 0.00 -0.83 0.89

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ResApp Health has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if ResApp Health has efficiently used its assets last year compared to the DE Healthcare Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ResApp Health improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ResApp Health's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ResApp Health has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is ResApp Health's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ResApp Health's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ResApp Health is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ResApp Health has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of ResApp Health's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • ResApp Health has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ResApp Health Company Filings, last reported 4 months ago.

DB:NUG Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 9.30 0.00 6.81
2018-09-30 9.30 0.00 6.81
2018-06-30 5.54 0.00 3.40
2018-03-31 5.54 0.00 3.40
2017-12-31 8.56 0.00 5.80
2017-09-30 8.56 0.00 5.80
2017-06-30 11.35 0.00 8.55
2017-03-31 11.35 0.00 8.55
2016-12-31 13.70 0.00 12.17
2016-09-30 13.70 0.00 12.17
2016-06-30 16.05 0.00 13.74
2016-03-31 16.05 0.00 13.74
2015-12-31 5.39 0.00 2.68
2015-09-30 5.39 0.00 2.68
2015-06-30 0.48 0.00 4.10
2015-03-31 0.48 0.00 4.10
2014-12-31 0.66 0.00 0.36
2014-09-30 0.66 0.00 0.36
2014-06-30 0.12 0.00 0.04
2014-03-31 0.12 0.00 0.04
2013-12-31 0.50 0.00 0.55
2013-09-30 0.50 0.00 0.55
2013-06-30 0.17 0.00 0.15
2013-03-31 0.17 0.00 0.15
2012-12-31 0.50 0.00 0.52
2012-09-30 0.50 0.00 0.52
2012-06-30 1.09 0.00 0.95
  • ResApp Health has no debt.
  • ResApp Health has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • ResApp Health has sufficient cash runway for 1.1 years based on current free cash flow.
  • ResApp Health has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 38% each year.
X
Financial health checks
We assess ResApp Health's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ResApp Health has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is ResApp Health's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ResApp Health dividends. Estimated to be 0% next year.
If you bought €2,000 of ResApp Health shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ResApp Health's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ResApp Health's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:NUG Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 1.5%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:NUG Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2021-06-30 0.00 1.00
2020-06-30 0.00 1.00
2019-06-30 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ResApp Health has not reported any payouts.
  • Unable to verify if ResApp Health's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ResApp Health's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ResApp Health has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of ResApp Health's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess ResApp Health's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ResApp Health afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ResApp Health has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of ResApp Health's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Tony Keating
COMPENSATION A$312,249
TENURE AS CEO 3.8 years
CEO Bio

Dr. Anthony Keating, also known as Tony, has been Chief Executive Officer and Managing Director of ResApp Health Limited since July 2, 2015. Dr. Keating served as a Director of Commercial Engagement for Engineering and Ict at UniQuest Pty Limited. Dr. Keating represent Bilexys in Chicago, as well as a suite of additional Australian water innovations - including Cloevis and other technologies from The University of Queensland’s Advanced Water Management Centre. Dr. Keating has been a Director of ResApp Health Limited since July 2, 2015. Dr. Keating holds a Bachelor of Engineering, a Master of Engineering Science and a Doctor of Philosophy (Mechanical Engineering) from The University of Queensland. He also has an Executive Certificate of Management and Leadership from the MIT Sloan School of Management and is a Graduate Member of the Australian Institute of Company Directors.

CEO Compensation
  • Tony's compensation has been consistent with company performance over the past year.
  • Tony's remuneration is about average for companies of similar size in Germany.
Management Team

Tony Keating

TITLE
CEO, MD & Director
COMPENSATION
A$312K
TENURE
3.8 yrs

Brian Leedman

TITLE
Vice President of Corporate Affairs
COMPENSATION
A$190K

Kay Taylor

TITLE
Vice President of Strategic Development & Operations

Udantha Abeyratne

TITLE
Chief Scientist & Scientific Advisor

Nicki Farley

TITLE
Company Secretary
AGE
42
TENURE
6.5 yrs

Clas Källander

TITLE
Founder and Director of R&D of Cavidi AB
COMPENSATION
A$109K

Paul Porter

TITLE
Scientific Advisor
Board of Directors Tenure

Average tenure of the ResApp Health board of directors in years:

2.8
Average Tenure
  • The average tenure for the ResApp Health board of directors is less than 3 years, this suggests a new board.
Board of Directors

Roger Aston

TITLE
Non-Executive Chairman
COMPENSATION
A$90K
AGE
62
TENURE
3.8 yrs

Tony Keating

TITLE
CEO, MD & Director
COMPENSATION
A$312K
TENURE
3.8 yrs

Udantha Abeyratne

TITLE
Chief Scientist & Scientific Advisor

Chris Ntoumenopoulos

TITLE
Non-Executive Director
COMPENSATION
A$55K
TENURE
4.3 yrs

Paul Porter

TITLE
Scientific Advisor

Philip Currie

TITLE
Member of Scientific Advisory Board
TENURE
1.8 yrs

Nathan Edmund Buzza

TITLE
Non-Executive Director
COMPENSATION
A$28K
TENURE
1.4 yrs

Scott Claxton

TITLE
Member of Scientific Advisory Board
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
27. Sep 18 Sell Freeman Road Pty Ltd Company 11. Aug 17 13. Sep 18 -4,900,000 €0.16 €-382,023
20. Sep 18 Buy FIL Limited Company 19. Sep 18 19. Sep 18 3,565,962 €0.14 €488,288
20. Sep 18 Sell FIL Limited Company 31. Oct 17 02. Jul 18 -2,818,035 €0.09 €0
20. Sep 18 Buy FIL Limited Company 20. Jun 17 02. Jul 18 8,148,473 €0.20 €0
X
Management checks
We assess ResApp Health's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ResApp Health has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

ResApp Health Limited develops and commercializes the ResApp technology to provide health care solutions for respiratory diseases. The company offers telehealth companies with point of care diagnostic solutions to integrate into their platforms. It also provides SMARTCOUGH-C, a multi-site and double blind prospective clinical study to investigate ResAppDx for the diagnosis of respiratory disease in infants and children using cough sounds based on the diagnosis of pneumonia, croup, bronchiolitis, asthma/reactive airways disease, lower respiratory tract disease, and upper respiratory tract infection. The company was formerly known as Narhex Life Sciences Limited. ResApp Health Limited was founded in 2014 and is headquartered in Brisbane, Australia.

Details
Name: ResApp Health Limited
NUG
Exchange: DB
Founded: 2014
A$61,886,823
693,130,512
Website: http://www.resapphealth.com.au
Address: ResApp Health Limited
127 Creek Street,
Level 8,
Brisbane,
Queensland, 4000,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX RAP Ordinary Shares Australian Securities Exchange AU AUD 12. Jan 2005
DB NUG Ordinary Shares Deutsche Boerse AG DE EUR 12. Jan 2005
CHIA RAP Ordinary Shares Chi-X Australia AU AUD 12. Jan 2005
Number of employees
Current staff
Staff numbers
0
ResApp Health employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/19 22:54
End of day share price update: 2019/05/17 00:00
Last estimates confirmation: 2019/05/01
Last earnings filing: 2019/02/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.